Drugs / Lutikizumab
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06067568 | Sep 2023 → Feb 2024 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01668511 | Sep 2012 → Oct 2013 | osteoarthritis | AbbVie | Completed | No outcome recorded |
| Phase 29 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT06972446 | Jun 2025 → Feb 2027 expected | rheumatoid arthritis | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06865105 | Apr 2025 → Dec 2027 expected | psoriatic arthritis | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06718101 | Dec 2024 → May 2027 expected | atopic eczema | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06548542 | Sep 2024 → Jan 2030 expected | Crohn disease | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06524635 | Aug 2024 → Feb 2027 expected | atopic eczema, hidradenitis suppurativa | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06257875 | Mar 2024 → Sep 2027 expected | ulcerative colitis | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05139602 | Dec 2021 → Dec 2027 expected | hidradenitis suppurativa | AbbVie | Active not recruiting | Met primary |
| Phase 2 | NCT02384538 | Mar 2015 → Jul 2016 | arthropathy, erosive | AbbVie | Completed | Missed primary |
| Phase 2 | NCT02087904 | Jun 2014 → Jun 2016 | osteoarthritis, knee | AbbVie | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06468228 | Jun 2024 → Dec 2026 expected | hidradenitis suppurativa | AbbVie | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-01-08 | AbbVie | Results Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3 abbvie.com ↗
AbbVie (NYSE: ABBV) today announced Phase 2 results showing adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg every other week or 300 mg weekly achieved higher response rates |
| 2015-11-03 | AbbVie | Results AbbVie's Leadership and Innovation in Immunology Showcased at the American College of Rheumatology Annual Meeting with More Than 40 Abstracts on HUMIRA® (adalimumab) and Investigational Medicines Across Multiple Inflammatory Diseases abbvie.com ↗
Dual Variable Domain-Immunoglobulin (Dvd-Ig™) Abt-981 Simultaneously And Dose-Dependently Inhibits Interleukin-1 Αlpha And -1 Βeta In Subjects With Knee Osteoarthritis |
All press releases naming this drug 2 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutikizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05139602 ↗ |
| Known as | A-1234138 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594518 ↗ |
| Known as | ABT-981 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02384538 ↗ |
| Action | Inhibit | “an anti-interleukin-1α/β dual variable domain immunoglobulin” PMID 28964890 ↗ Sep 2017 |
| Modality | Monoclonal antibody | — CHEMBL4594518 ↗ |
| Modality | Protein / enzyme biologic | “a human dual variable domain immunoglobulin” PMID 28964890 ↗ Sep 2017 |
| Route | Subcutaneous | “multiple subcutaneous (SC) injections of ABT-981” PMID 28964890 ↗ Sep 2017 |
| Target | IL1A | “Interleukin-1 alpha inhibitor” CHEMBL4594518 ↗ |
| Target | IL1B | “Interleukin-1 beta inhibitor” CHEMBL4594518 ↗ |